Activated granulocyte (None established; "AG" is sometimes used informally, but not as a standard abbreviation.)

An *activated granulocyte* refers broadly to any member of the granulocyte family—primarily neutrophils, eosinophils, basophils—that has been stimulated by infection-, injury-, or inflammation-related signals. Upon activation these cells rapidly deploy effector mechanisms including phagocytosis; degranulation with release of enzymes/toxic proteins; production and secretion of pro-inflammatory cytokines; formation of extracellular traps; and even antigen presentation under certain conditions. These activities make them central players in acute immune responses but also contributors to chronic inflammation and tissue damage when dysregulated. The term does not denote one specific molecule or druggable target but rather describes an important functional state within the innate immune system relevant across many disease contexts including infections, allergies/asthma, autoimmune disorders, and cancer progression through immunomodulatory roles.

Other names

Activated neutrophilActivated eosinophilActivated basophilPolymorphonuclear leukocyte (when referring to neutrophils)PMN (for neutrophils)

For drugs affecting activated granulocytes indirectly: - Inhibition of cytokine signaling pathways that drive activation/proliferation/function (e.g., JAK/STAT pathway inhibition by ruxolitinib). - Depletion via antibodies targeting surface markers on these cells in research settings.